So, if someone with the characteristics of this treatment group takes semaglutide 2.4mg on the standard 16 week titration schedule, they can expect a (geometric) average reduction of 48.6% The way the researchers are interpreting their findings is that the average reduction in uACR is -48.6% BUT if the placebo group is a correct representation of doing nothing (and they did nothing) they could have expected their uACR to go up 7.4% over those same 24 weeks, so in theory they end up 52.1% better off based on the geometric mean
This is common and not your fault
"The prescribing information for Wegovy [also] contains a boxed warning to inform health care professionals and patients about the risk of thyroid C-cell tumors," the FDA said, so it should not be used by people with a personal or family history of medullary thyroid carcinoma
Tirzepatide Known by the brand names Mounjaro and Zepbound , tirzepatide is FDA-approved for type 2 diabetes and used off-label for weight loss
At the center of this system are two heavy hitters: glutathione and Vitamin C
Fluoxetine is taken orally, so this is relevant in principle